MISSION VIEJO, Calif., Aug. 04, 2017 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ:MYND), a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error treatment in mental health, announced the addition of Leila Colgan, as Vice President of Sales and Marketing, an experienced diagnostic/pharma executive to its ranks.
Ms. Colgan is an accomplished, results-oriented professional with over 20 years of leadership experience in sales and marketing within the pharmaceutical, biotech and oncology/genomic diagnostic space including organizations such as Clarient, a GE Healthcare Co, (acquired by NeoGenomics in 2015) Amgen, Inc., AstraZeneca, Pfizer (Agouron), Merck & Co. Inc. and Abbott Laboratories. Her depth of industry knowledge and her proven ability to build high-performance teams will be a key in leading the Company’s revenue growth.
Ms. Colgan has consistently exceeded corporate and market share growth targets, and is a recipient of multiple national and local achievement awards throughout her career. She is a visionary executive known for championing business growth and innovation through sales leadership, marketing, business development, and operational oversight while elevating organizations into top revenue-generating entities. An insightful leader with a reputation for forging profitable partner/customer relationships, and aligning sales/promotion functions to maximize revenue and return on investment (ROI), Ms. Colgan received her Bachelor’s of Arts and her Executive MBA from Pepperdine University, graduating with Beta Gamma Sigma Honors.
George Carpenter, MYnd’s CEO, said “Leila’s market expertise, industry connections, sales acumen, and ability to build key relationships will be key to our success, and is a fantastic addition to our growing world class executive team.”
Ms. Colgan stated “I am thrilled to have the opportunity to lead the sales and marketing efforts at MYnd Analytics as we provide better tools for mental health professionals to help decrease trial and error prescribing for their patients.”
About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online® is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
Forward-looking Statements
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as MYnd’s ability to successfully expand into various market channels, the ability of its products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses and MYnd’s ability to expand globally in areas where there is an opportunity to improve treatment in mental health, as well as those risks and uncertainties set forth in MYnd’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Contact: Stan Wunderlich Investor Relations,CFSG1 800-625-2236 info@cfsg1.com www.launchpadir.net
